DOCSLIB.ORG

Infection Research Reagents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Infection Research Reagents Infection Research Reagents Synthetic Antimicrobials Chlorhexidine Dihydrochloride 5g / 25g [C1254] Ofloxacin 5g / 25g [O0403] Ciprofloxacin 5g / 25g [C2510] Sulfanilamide 25g / 100g / 500g [S0119] Infection Research Clofazimine 1g / 5g [C2866] Sulfadiazine 25g [S0579] Enrofloxacin 5g / 25g [E0786] Sulfadimethoxine 25g [S0359] Reagents Fleroxacin 5g / 25g [F0646] Sulfabenzamide 25g [S0582] Flumequine 5g / 25g [F0832] Sulfathiazole 25g / 100g / 500g [S0272] Anti-Influenza Virus Monoclonal Antibodies / Levofloxacin 5g / 25g [L0193] Trimethoprim 25g 100g / 500g [T2286] Anti-Influenza A Virus Neuraminidase N1 Monoclonal Antibody 0.2mL [A2407] Lomefloxacin Hydrochloride 5g / 25g [L0216] Immunogen:Influenza A/Beijing/262/95 Clone:2-3B Isotype:IgG1 Host:Mouse Product Form : Protein G purified, mouse monoclonal antibody, 0.05 % NaN3 , 1% BSA 0.2mL Methotrexate Hydrate 1g / 5g [M1664] Anti-Influenza A Virus Hemagglutinin H3 Monoclonal Antibody [I0779] Immunogen :Purified hemagglutinin H3 (Influenza A/sydney/5/97) Clone:1G8 Isotype:IgG3 Host:Mouse Product Form:Protein G purified, mouse monoclonal antibody, 0.05 % NaN3 , 1% BSA Anti-Influenza A Virus Neuraminidase N2 Monoclonal Antibody 0.2mL [A2380] Immunogen:Influenza A/sydney/5/97 Clone:1-4B Isotype:IgG1 Host:Mouse Product Form:Protein G purified, mouse monoclonal antibody, 0.05 % NaN3 , 1% BSA Antifungals Anti-Influenza A Virus Nucleoprotein Monoclonal Antibody 0.2mL [A2406] Immunogen:Influenza A/Beijing/262/95 Clone:17 Isotype:IgG2a Host:Mouse Product Form:Protein G purified, mouse monoclonal antibody, 0.05 % NaN3 , 1% BSA Amorolfine Hydrochloride 200mg / 1g [A2161] (+)-Griseofulvin 5g / 25g [G0384] Atovaquone 200mg / 1g [A2545] IPBC 25g / 100g [I0666] Antivirals Butenafine Hydrochloride 1g / 5g [B3293] Isoconazole Nitrate 5g [I0834] Butoconazole Nitrate 1g [B4801] Itraconazole 5g / 25g [I0732] Abacavir 1g / 5g [A2694] Moronic Acid 5mg / 25mg [M2610] Climbazole 25g / 500g [C2025] Ketoconazole 1g / 5g [K0045] Acyclovir 1g / 5g / 25g [A1915] Moroxydine Hydrochloride 5g / 25g [M2443] Clotrimazole 5g / 25g [C2867] Magnolol 200mg / 1g [D3971] Adefovir Dipivoxil 100mg / 1g [A2414] NBD-556 25mg / 100mg [N1090] Econazole Nitrate 5g / 25g [E0957] Miconazole Nitrate 5g / 25g [M1769] Amantadine 5g / 25g [A2318] Nelfinavir Mesylate Hydrate 25mg / 100mg [N0986] Fenhexamid 200mg / 1g [F0967] Piroctone Olamine 1g / 5g [P2178] Amantadine Hydrochloride 25g / 250g [A0588] Nevirapine 200mg [N0922] Fenticonazole Nitrate 200mg [F1008] Terbinafine Hydrochloride 1g / 5g [D2049] Brivudine 100mg [B3404] Nitazoxanide 200mg / 1g / 5g [N1031] Fluconazole 1g / 5g [F0677] Tolnaftate 1g / 5g [T3059] Clemizole Hydrochloride 25mg / 100mg [C3468] Penciclovir 200mg / 1g [P2164] 5-Fluorocytosine 1g / 5g / 25g [F0321] Voriconazole 100mg / 1g [V0116] Cytarabine 1g / 5g [C2035] Pirodavir 10mg / 50mg [P2665] ddA 100mg [D3065] Plerixafor 50mg / 250mg [P2678] Decitabine 20mg / 100mg [A2232] PSI-6206 200mg / 1g [D4823] Reagents for Verotoxin-producing E. coli (VTEC)-related Research Didanosine 100mg / 500mg [D3066] Resiquimod 25mg / 100mg [R0197] Gb3-β-MP 100mg [M1767] 1-Docosanol 25g / 500g [D0964] Ribavirin 100mg / 500mg [R0077] Human Serum Albumin-Gb3 0.1mg/vial [H1718] Efavirenz 5g [E0997] Rimantadine Hydrochloride 5g [R0070] Anti-Gb3 Monoclonal Antibody 0.1mg/vial [A2506] Emtricitabine 25mg / 250mg [E1007] Ritonavir 200mg / 1g [R0116] Immunogen:Purified glycolipid Gb3 adsorbed to Salmonella Minnesota Clone:BGR23 Isotype:IgG2b Product Form :Purified mouse monoclonal antibody, 0.05 % NaN3 Entecavir Monohydrate 50mg / 200mg [E0899] Stavudine 1g / 5g [D3580] Anti-Gb3 Monoclonal Antibody Biotin Conjugate 0.1mg/vial [A2822] Immunogen:Purified glycolipid Gb3 adsorbed to Salmonella Minnesota Clone:BGR23 Isotype:IgG2b Product Form:Hybridoma culture supernatant (containing 10% fetal bovine serum), 0.05 % NaN3 Famciclovir 500mg [F0842] T-1105 1g / 5g [H1485] Fialuridine 10mg [D4200] Tenofovir Hydrate 1g / 5g [T3006] For Laboratory Use, Research Purposes Only. Ganciclovir Hydrate 5g / 25g [G0315] Tilorone Dihydrochloride 100mg / 1g [T2836] Idoxuridine 1g / 5g / 25g [I0258] Tizoxanide 25mg / 100mg [T3862] Imiquimod 100mg / 1g [I0747] Trifluridine 100mg / 1g [T2511] Infection For further information please refer to our website at www.TCIchemicals.com. ▼ ▼ ▼ Inosine 25g / 500g [I0037] Valacyclovir Hydrochloride 100mg / 1g [V0111] Inosine Pranobex 100mg / 1g [I1037] Valganciclovir Hydrochloride 250mg / 1g [V0158] Lamivudine 100mg / 1g [L0217] Vidarabine Monohydrate 1g / 5g [V0098] Mizoribine 50mg / 250mg [M2399] Zanamivir Hydrate 100mg [Z0023] Ordering and Tel : +32 (0)3 735 07 00 Tel : +44 (0)1865 784560 Tel : 800-988-0390 / 021-67121386 Customer Service Fax : +32 (0)3 735 07 01 Fax : +44 (0)1865 784561 Fax : 021-6712-1385 Zidovudine 1g / 5g [A2052] E-mail : [email protected] E-mail : [email protected] E-mail : [email protected] Tel : 800-423-8616 / 503-283-1681 Tel : +49 (0)6196 64053-00 Tel : 1800 425 7889 / 044-2262 0909 Tel : +81 (0)3-5640-8878 Fax : 888-520-1075 / 503-283-1987 Fax : +49 (0)6196 64053-01 Fax : 044-2262 8902 Fax : +81 (0)3-5640-8902 E-mail : [email protected] E-mail : [email protected] E-mail : [email protected] E-mail : [email protected] Availability, price or specification of the listed products are subject to change without prior notice. Reproduction forbidden without the prior written consent of Tokyo Chemical Industry Co., Ltd. www.TCIchemicals.com LL029E 20200325 Infection Research Reagents Antibiotics Antiprotozoals 7-ACA 5g / 25g [A1266] Cyclosporin A 100mg / 1g [C2408] Amodiaquin Dihydrochloride Dihydrate Mebendazole 5g / 25g [M2273] Acriflavine 25g [A0134] Daptomycin 100mg [D4229] 5g / 25g [A3133] Mefloquine Hydrochloride 1g [M2313] Acriflavine Hydrochloride 25g / 100g [A0677] Daunorubicin Hydrochloride Arprinocid 50mg / 250mg [A3146] Metronidazole 25g / 500g [M0924] Acrinol Monohydrate 25g [A0136] 20mg / 100mg [D4532] p-Arsanilic Acid 25g / 500g [A0530] Miltefosine 100mg / 1g [M2445] 7-ADCA 5g / 25g [A2075] Dimetridazole 25g [D1564] Artemether 5g / 25g [A2190] Moxidectin 250mg / 1g [M3136] Amoxicillin Trihydrate 5g / 25g [A2099] Doxorubicin Hydrochloride 25mg / 100mg [D4193] Artemisinin 1g / 5g [A2118] Nifuratel 5g / 25g [N1167] Ampicillin Trihydrate 5g / 25g [A2092] Doxycycline Hyclate 5g / 25g [D4116] Artesunate 5g / 25g [A2191] Nitarsone 200mg / 1g [N0964] Anisomycin 25mg / 100mg [A2613] Erythromycin 5g / 25g [E0751] Atovaquone 200mg / 1g [A2545] Nitazoxanide 200mg / 1g / 5g [N1031] 6-APA 5g / 25g [A0800] Florfenicol 1g / 5g [F0811] Atoxyl 25g [A0531] Ornidazole 5g / 25g [O0417] Azithromycin Dihydrate 1g / 5g [A2076] Fosfomycin Disodium Salt 5g / 25g [F0889] Bithionol 25g / 500g [T0865] Oxfendazole 1g / 5g [O0391] Azomycin 1g / 5g [N0891] Fradiomycin Sulfate 25g [F0649] Bithionol Disodium Salt 25g [T0406] Oxibendazole 100mg / 500mg [O0499] Fusidic Acid 1g / 5g [F1007] Chloroquine Diphosphate Aztreonam 500mg / 5g [A2466] Paromomycin Sulfate 1g / 5g [P2092] 25g / 100g / 500g [C2301] Bleomycin Sulfate (mixture) 10mg / 50mg [B3972] G418 Disulfate 1g / 5g [G0349] Piperaquine Tetraphosphate Tetrahydrate Clofazimine 1g / 5g [C2866] Cefazolin Sodium Salt 5g / 25g [C2242] Geldanamycin 10mg [G0334] 5g / 25g [P1987] Diclazuril 1g / 5g [D5457] Cefcapene Pivoxil Hydrochloride Monohydrate Gentamicin Sulfate 1g / 5g [G0383] Pyrimethamine 1g / 5g [P2037] 200mg / 1g [C2623] Hygromycin B 200mg / 1g [H1509] Dihydroartemisinin 1g / 5g [D3793] Quinine 25g / 100g [Q0028] Cefdinir 1g / 5g [C3111] Kanamycin Monosulfate 5g / 25g [K0047] Doxycycline Hyclate 5g / 25g [D4116] Quinine Hydrochloride Dihydrate 25g [Q0030] Cefditoren Pivoxil 200mg [C2856] Leucomycins 5g / 25g [K0046] Febantel 1g / 5g [F0922] Rafoxanide 1g [R0108] Cefmetazole Sodium Salt 250mg / 1g [C3029] Lincomycin Hydrochloride Monohydrate Flubendazole 5g / 25g [F0825] Secnidazole 1g / 5g [S0911] Cefotaxime Sodium Salt 5g / 25g [C2224] 5g / 25g [L0166] Hydroxychloroquine Sulfate 5g / 25g [H1306] Sulfadoxin 5g / 25g [S0899] Cefotetan 25mg / 250mg [C2936] Meropenem Trihydrate 1g / 5g [M2279] Imidocarb Dipropionate 1g / 5g [I0957] Sulfalene 5g / 25g [S0917] Cefpirome Sulfate 1g / 5g [C3007] Minocycline Hydrochloride 1g / 5g [M2288] Levamisole Hydrochloride 10g / 25g [T1215] Tetramisole Hydrochloride 10g [T3663] Cefsulodin Sodium Salt 200mg / 1g [C2598] Oxacillin Sodium Salt Monohydrate Lumefantrine 5g / 25g [L0256] Tinidazole 5g / 25g [T3058] 1g / 5g / 25g [O0353] Ceftazidime 5g / 25g [C2225] Tizoxanide 25mg / 100mg [T3862] Paromomycin Sulfate 1g / 5g [P2092] Ceftezole 5g / 25g [C2770] Penicillin G Potassium Salt 25g [P1772] Ceftizoxime 1g / 5g [C2622] Penicillin G Sodium Salt 1g / 5g [P1770] Ceftriaxone Disodium Salt Hemiheptahydrate 5g / 25g [C2226] Polymyxin B Sulfate 1g / 5g [P1923] Cephalexin Monohydrate 5g / 25g [C2248] Rifampicin 5g / 25g [R0079] Cephalothin 5g / 25g [C2769] Rifaximin 1g / 5g [R0101] Cephradine Monohydrate 1g / 5g [C2988] Roxithromycin 5g / 25g [R0164] Chloramphenicol 25g / 250g [C2255] Secnidazole 1g / 5g [S0911] Chloramphenicol Palmitate Spiramycin 5g / 25g [S0575] 200mg / 1g / 5g [C3258] Streptomycin Sulfate 25g / 500g [S0585] Clarithromycin 1g / 5g / 25g [C2220] Sulbactam 5g / 25g [S0868] Clindamycin Hydrochloride Monohydrate Tetracycline Hydrochloride 25g / 100g [T2525] 5g / 25g [C2256] Thiamphenicol 5g / 25g [T2802] Clindamycin Phosphate 5g / 25g [C2257] Tobramycin 5g / 25g [T2503] Cloxacillin Sodium Salt Monohydrate Wortmannin 20mg [W0007] 1g / 5g [C2244] www.TCIchemicals.com
Load more

Recommended publications
  • Newer Trends in the Management of Genital Herpes
    Review NNewerewer trendstrends inin thethe mmanagementanagement ofof genitalgenital herpesherpes Article AAmiyamiya KKumarumar NNath,ath, DDevinderevinder MohanMohan ThappaThappa Department of Dermatology ABSTRACT and STD, Jawaharlal Institute of Postgraduate Medical Management of genital herpes is complex. Apart from using the standard antivirals, an Education and Research (JIPMER), Pondicherry - 605 ideal management protocol also needs to address various aspects of the disease, including 006, India the psychological morbidity. Oral acyclovir, valacyclovir or famciclovir are recommended for routine use. Long-term suppressive therapy is effective in reducing the number of AAddressddress forfor ccorrespondence:orrespondence: recurrences and the risk of transmission to others. Severe or disseminated disease may Dr. Devinder Mohan Thappa, require intravenous therapy. Resistant cases are managed with foscarnet or cidofovir. Genital Department of Dermatology herpes in human immunodeÞ ciency virus-infected individuals usually needs a longer duration and STD, JIPMER, of antiviral therapy along with continuation of highly active anti retroviral therapy (HAART). Pondicherry - 605 006, India. E-mail: [email protected] Genital herpes in late pregnancy increases the risk of neonatal herpes. Antiviral therapy and/or cesarean delivery are indicated depending on the clinical circumstance. Acyclovir appears to be safe in pregnancy. But, there is limited data regarding the use of valacyclovir and famciclovir in pregnancy. Neonatal herpes requires a higher dose of acyclovir given intravenously for a longer duration. Management of the sex partner, counseling and prevention advice are equally important in appropriate management of genital herpes. Vaccines till date have been marginally effective. Helicase–primase inhibitors, needle-free mucosal vaccine and a new microbicide product named VivaGel may become promising treatment options in the future.
    [Show full text]
  • The Effects of Atopy and Asthma on in Vivo Human Nasal Responses to Toll
    The effects of atopy and asthma on in vivo human nasal responses to Toll-like receptor agonists Dr Akhilesh Jha A thesis submitted for the degree of Doctor of Philosophy (PhD) Centre for Respiratory Infection National Heart and Lung Institute (NHLI), St Mary’s Campus Imperial College London, Norfolk Place, London W2 1PG July 2018 Abstract Acute respiratory viral infections cause significant morbidity and mortality, especially in vulnerable individuals, and it is important to study viral pathogenesis and the host immune response in humans. Toll-like receptors (TLRs) play a critical role in the detection of viral nucleic acids, and airway TLR receptors respond to nucleic acid patterns in the RNA viruses that cause respiratory infections. However, a reliable method of measuring mucosal innate immune responses to viral infections is lacking. TLR3 agonists (poly(I:C) and poly-ICLC) and the combined TLR7/8 agonist (resiquimod, R848) are synthetic analogues of double stranded RNA (dsRNA) and single stranded RNA (ssRNA) respectively. Nasal challenge with these TLR agonists was carried out, and serial sampling using nasosorption and nasal curettage was performed. Mucosal immune responses were measured and the effect of different host factors (e.g. asthma) on these responses was studied. Poly(I:C) and poly-ICLC were well tolerated but failed to induce significant and reliable nasal mucosal innate immune responses. R848 at a higher dose (10 µg/100 µL per nostril) induced significant mucosal interferon and cytokine responses but caused mild to moderate flu-like symptoms in three out of nine volunteers. A lower dose of R848 (0.02 µg/kg/100 µL, mean dose 1.5 µg/100 µL) was subsequently utilised in three groups of volunteers: healthy non-atopic (n=12), allergic rhinitis (n=12) and allergic asthma (n=11).
    [Show full text]
  • Inclusion and Exclusion Criteria for Each Key Question
    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
    [Show full text]
  • Bioinformatics Review of the Role of HSV-1 in Alzheimer's Disease
    Advances in Alzheimer’s Disease, 2020, 9, 57-75 https://www.scirp.org/journal/aad ISSN Online: 2169-2467 ISSN Print: 2169-2459 Bioinformatics Review of the Role of HSV-1 in Alzheimer’s Disease Brian T. Reiss1, Meade C. Eggleston1, Arah C. Godbole1, Julia A. Marut1, Cecelia M. McCann1, Jessica A. Cottrell1, Tinchun Chu1, Sulie L. Chang1,2* 1Department of Biological Sciences, Seton Hall University, South Orange, NJ, USA 2Institute of Neuroimmune Pharmacology, Seton Hall University, South Orange, NJ, USA How to cite this paper: Reiss, B.T., Eg- Abstract gleston, M.C., Godbole, A.C., Marut, J.A., McCann, C.M., Cottrell, J.A., Chu, T.C. and Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the Chang, S.L. (2020) Bioinformatics Review progressive loss of cognitive functions in affected individuals. Brain tissue of the Role of HSV-1 in Alzheimer’s Dis- pathology is associated with the formation of senile plaques which result from ease. Advances in Alzheimer’s Disease, 9, 57-75. the over-production of amyloid β (Aβ), due to the cleavage of a membrane https://doi.org/10.4236/aad.2020.93005 bound glycoprotein. It is unclear what causes AD and its associated patholo- gies, but age and genetic predisposition play an import role in the likelihood Received: June 11, 2020 Accepted: September 6, 2020 of disease development. Studies have shown that the reactivation of latent Published: September 9, 2020 herpes simplex virus 1 (HSV-1) infection can lead to the neuropathy of acute herpes simplex encephalitis (HSE), which causes similar symptoms to AD.
    [Show full text]
  • Activation of Anti-Hepatitis C Virus Responses Via Toll-Like Receptor 7
    Activation of anti-hepatitis C virus responses via Toll-like receptor 7 Jongdae Lee*, Christina C. N. Wu*†, Ki Jeong Lee‡, Tsung-Hsien Chuang§, Kyoko Katakura*, Yu-Tsueng Liu*†, Michael Chan†, Rommel Tawatao†, Michelle Chung*, Carol Shen*, Howard B. Cottam†, Michael M. C. Lai‡, Eyal Raz*, and Dennis A. Carson†¶ *Department of Medicine, University of California at San Diego, La Jolla, CA 92093-0663; †Moores Cancer Center, University of California at San Diego Medical Center, La Jolla, CA 92093-0820; ‡Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033; and §Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037 Contributed by Dennis A. Carson, December 15, 2005 IFN-␣ is used to suppress the replication of hepatitis C virus (HCV) in HCV replicon cells. The IRFs can both foster type I IFN in chronically infected patients with partial success. Here we production (18) and enhance the antiviral activity of these present evidence showing that a ligand of Toll-like receptor 7 cytokines (19). Thus, pharmacologic agents that activate IRFs in (TLR7) can induce anti-HCV immunity not only by IFN induction, but hepatocytes may exert direct anti-HCV effects, as well as po- also through an IFN-independent mechanism. Human hepatocyte tentiate IFN action. line Huh-7 carrying an HCV replicon expressed TLR7, and activation Pharmacologic inhibitors of the enzyme inosine monophos- of the receptor induced several antiviral genes including IFN phate dehydrogenase (IMPDH), including ribavirin and mizor- regulatory factor-7. Inhibitors of the enzyme inosine monophos- ibine, have been reported to have activity against RNA viruses phate dehydrogenase augmented both IFN-dependent and -inde- (18–20).
    [Show full text]
  • Annual Report 2016
    Annexes to the annual report of the European Medicines Agency 2016 Annex 1 – Members of the Management Board ............................................................... 2 Annex 2 - Members of the Committee for Medicinal Products for Human Use ...................... 4 Annex 3 – Members of the Pharmacovigilance Risk Assessment Committee ........................ 6 Annex 4 – Members of the Committee for Medicinal Products for Veterinary Use ................. 8 Annex 5 – Members of the Committee on Orphan Medicinal Products .............................. 10 Annex 6 – Members of the Committee on Herbal Medicinal Products ................................ 12 Annex 7 – Committee for Advanced Therapies .............................................................. 14 Annex 8 – Members of the Paediatric Committee .......................................................... 16 Annex 9 – Working parties and working groups ............................................................ 18 Annex 10 – CHMP opinions: initial evaluations and extensions of therapeutic indication ..... 24 Annex 10a – Guidelines and concept papers adopted by CHMP in 2016 ............................ 25 Annex 11 – CVMP opinions in 2016 on medicinal products for veterinary use .................... 33 Annex 11a – 2016 CVMP opinions on extensions of indication for medicinal products for veterinary use .......................................................................................................... 39 Annex 11b – Guidelines and concept papers adopted by CVMP in 2016 ...........................
    [Show full text]
  • Naive Alum | IMQ-Cpg
    US010485861B2 United States Patent (10 ) Patent No.: US 10,485,861 B2 Stary et al. (45 ) Date of Patent : Nov. 26 , 2019 (54 ) NANOPARTICLE -BASED COMPOSITIONS Related U.S. Application Data ( 71) Applicants : President and Fellows of Harvard (60 ) Provisional application No. 61/ 783,439 , filed on Mar. College , Cambridge , MA (US ) : 14 , 2013 . Massachusetts Institute of (51 ) Int. CI. Technology , Cambridge , MA (US ); The A61K 39/118 (2006.01 ) Brigham and Women's Hospital, Inc., A61K 45/06 ( 2006.01) Boston , MA (US ) (Continued ) (52 ) U.S. CI. (72 ) Inventors : Georg Stary, Brookline, MA (US ) ; CPC A61K 39/118 (2013.01 ) ; A61K 31/4745 Aleksandar Filip Radovic -Moreno , ( 2013.01 ) ; A61K 31/711 ( 2013.01) ; State College , PA (US ) ; Pamela A. (Continued ) Basto , Cambridge, MA (US ) ; Michael ( 58 ) Field of Classification Search N. Starnbach , Needham , MA (US ) ; CPC A61K 9/10 ; A61K 35/74 ; A61K 39/39 ; Robert S. Langer , Newton , MA (US ) ; A61K 39/522 ; A61K 39/55555 ; Omid C. Farokhzad , Waban , MA (US ) ; Ulrich Von Andrian , Chestnut (Continued ) Hill , MA (US ) ( 56 ) References Cited (73 ) Assignees: President and Fellows of Harvard U.S. PATENT DOCUMENTS College, Cambridge , MA (US ) ; Massachusetts Institute of 3,960,757 A 6/1976 Morishita et al . Technology , Cambridge, MA (US ) ; The 4,638,045 A 11/1987 Kohn et al . Brigham and Women's Hospital, Inc. , (Continued ) Boston , MA (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this WO WO1997028259 8/1997 patent is extended or adjusted under 35 WO WO1998016247 4/1998 U.S.C. 154 ( b ) by 0 days .
    [Show full text]
  • Breast Cancer Treatment with Imiquimod: Applying an Old Lotion to a New Disease
    Author Manuscript Published OnlineFirst on November 21, 2012; DOI: 10.1158/1078-0432.CCR-12-3138 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Breast cancer treatment with imiquimod: Applying an old lotion to a new disease Holbrook Kohrt, MD PhD Stanford University Cancer Institute Department of Medicine, Division of Oncology Stanford, CA 94305 Title: 79 characters Abstract: 49 words Text: 1200 words References: 12 references The author has no conflicts of interest. Running Title: Applying an old lotion to a new disease Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2012 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 21, 2012; DOI: 10.1158/1078-0432.CCR-12-3138 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Over the prior two decades, imiquimod, a toll-like receptor 7 agonist, has been applied to nearly fifty clinical settings. Due to its immunomodulatory role, the topical cream today for the first time, is being applied to cutaneous breast cancer in pre-clinical models and in a Phase 2 clinical trial. Manuscript In this issue of Clinical Cancer Research, two sets of authors from Demaria’s group, Dewan et al. (1) and Adams et al. (2) detail in companion papers the anti-tumor efficacy of imiquimod in first, a preclinical breast cancer model in combination with radiation (1), and second, a Phase 2, breast cancer clinical trial assessing safety and immunologic activity (2). Fifteen years after first approval by the Food and Drug Administration (FDA), imiquimod remains the only approved, active toll-like receptor (TLR) agonist (3).
    [Show full text]
  • Time-Resolved Effect of Interferon-Alpha 2A on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes
    pharmaceutics Article Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes Dirk Theile , Lelia Wagner , Cindy Bay, Walter Emil Haefeli and Johanna Weiss * Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany; [email protected] (D.T.); [email protected] (L.W.); [email protected] (C.B.); [email protected] (W.E.H.) * Correspondence: [email protected]; Tel.: +49-6221-5639402 Abstract: Interferon-alpha (IFN-α) is suggested to cause pharmacokinetic drug interactions by lowering expression of drug disposition genes through affecting the activities of nuclear factor kappa B (NF-kB) and pregnane X receptor (PXR). The time-resolved impact of IFN-α 2a (1000 U/mL; 5000 U/mL; 2 h to 30 h) on the activities of NF-kB and PXR and mRNA expression (5000 U/mL; 24 h, 48 h) of selected drug disposition genes and on cytochrome P450 (CYP3A4) activity in LS180 cells (5000 U/mL; 24 h, 48 h) was evaluated using luciferase-based reporter gene assays, reverse transcription polymerase chain reaction, and luminescence-based CYP3A4 activity assays. The cross- talk between NF-kB activation and PXR suppression was evaluated by NF-kB blockage (10 µM parthenolide). IFN-α 2a initially (2 h, 6 h) enhanced NF-kB activity 2-fold and suppressed PXR Citation: Theile, D.; Wagner, L.; activity by 30%. mRNA of CYP3A4 was halved, whereas UGT1A1 was increased (1.35-fold) after Bay, C.; Haefeli, W.E.; Weiss, J.
    [Show full text]
  • Immunosuppressant Ingredients, Immunostimulant Ingredients
    Immunosuppressant Ingredients, Immunostimulant Ingredients Immunosuppressant Ingredients Immunosuppressant ingredients are chemical and medicinal agents used for the suppression and regulation of immune responses. Pharmacologically speaking, these agents have varied mecha- nisms of action, such as regulation of inflammatory gene expression, suppression of lymphocyte signal transduction, neutralization of cytokine activity, and inhibition lymphocyte proliferation by agent-induced cytotoxicity. Common agents include glucocorticoids, alkylating agents, metabolic antagonists, calcineurin inhibitors, T-cell suppressive agents, and cytokine inhibitors. 5-Aminosalicylic Acid 25g / 500g [A0317] 5-Aminosalicylic acid (5-ASA) is commonly used as a gastrointestinal anti-inflammatory agent. It has in vitro and in vivo pharmacologic effects that decrease leukotriene production, scavenge for free radicals, and inhibits leukocyte chemotaxis et al. Azathioprine 5g / 25g [A2069] Azathioprine is a prodrug of 6-mercaptopurine (6-MP), which inhibits the synthesis of purine ribonucleotides and DNA/RNA. Cyclophosphamide Monohydrate 5g / 25g [C2236] Cyclophosphamide is an antitumor alkylating reagent involved in the cross-linking of tumor cell DNA. Cyclosporin A 100mg / 1g [C2408] Cyclosporin A is a cyclic polypeptide immunosuppressant. It inhibits the activity of T-lymphocytes, and the phosphatase activity of calcineurin. Dimethyl Fumarate 25g / 500g [F0069] Dimethyl fumarate has neuroprotective and immunomodulating effects. Fingolimod Hydrochloride 200mg / 1g [F1018] Fingolimod (FTY720) is an immunomodulatory agent. It is an agonist at sphingosine 1-phosphate (S1P) receptors, and inhibits lymphocyte emigra- tion from lymphoid organs. Iguratimod 25mg / 250mg [I0945] Iguratimod (T-614) is an agent with anti-inflammatory and immunomodulatory activities. Its activity functions by the inhibiting production of immune globulin and inflammatory cytokines such as TNF-α, IL-1β and IL-6, and used as a disease modifying anti-rheumatic drug (DMARD).
    [Show full text]
  • Rapid Host Immune Response and Viral Dynamics in Herpes Simplex Virus-2 Infection
    PERSPECTIVE Rapid host immune response and viral dynamics in herpes simplex virus-2 infection Joshua T Schiffer1,2 & Lawrence Corey1–3 Herpes simplex virus-2 (HSV-2) is periodically shed throughout rate of HIV five- to tenfold14. Men and women who have acquired the human genital tract. Although a high viral load correlates HSV-2 have a two- to threefold increased risk of HIV-1 infection15,16. with the development of genital ulcers, shedding also In countries in which sexually active adults have a high prevalence commonly occurs even when ulcers are absent, allowing for of HSV-2 infection, or in subpopulations such as men who have silent transmission during coitus and contributing to high sex with men where HSV-2 infection is common, HSV-2 is a major seroprevalence of HSV-2 worldwide. Frequent viral reactivation epidemiological driver of HIV-1 epidemics16–18. occurs within ganglia despite diverse and complementary Here we describe how frequent reactivation and release of HSV-2 host and viral mechanisms that predispose toward latency, from latency within neurons, as well as highly dynamic interactions suggesting that viral replication may be constantly occurring between replicating HSV-2 and the host cell-mediated immune in a small minority of neurons at these sites. Within genital response in genital tissues, contribute to observed disease manifes- mucosa, the in vivo expansion and clearance rates of HSV-2 are tations, high global prevalence and enhanced HIV acquisition risk. extremely rapid. Resident dendritic cells and memory HSV-2 We also highlight the unique challenges that the kinetics of these specific T cells persist at prior sites of genital tract reactivation viral-host interactions pose for antiviral and vaccine development.
    [Show full text]
  • Wo 2010/059253 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 27 May 2010 (27.05.2010) WO 2010/059253 A2 (51) International Patent Classification: 02140 (US). BERSHTEYN, Anna [US/US]; 25 Linden A61K 9/16 (2006.01) A61K 31/711 (2006.01) Avenue, Apartment 6, Somerville, MA 02143 (US). A61K 9/127 (2006.01) A61P 35/00 (2006.01) A61K 31/7105 (2006.01) (74) Agent: TREVISAN, Maria, A.; Wolf, Greenfield & Sacks, P.C , Federal Reserve Plaza, 600 Atlantic Avenue, (21) International Application Number: Boston, MA 02210-2206 (US). PCT/US2009/006290 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 24 November 2009 (24.1 1.2009) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (30) Priority Data: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/200,1 60 24 November 2008 (24.1 1.2008) US NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (71) Applicant (for all designated States except US): MAS- SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, SACHUSETS INSTITUTE OF TECHNOLOGY [US/ TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]